Dose-dependent effect of mineralcorticoid receptor inhibitor for chronic central serous chorioretinopathy

Session Details

Session Title: Free Paper Session 18: New Drug & Treatment Technology

Session Date/Time: Saturday 09/09/2017 | 14:30-16:00

Paper Time: 15:12

Venue: Room 120

First Author: : Y.Imamura JAPAN

Co Author(s): :    A. Suzuki   Y. Takano   J. Ogawa   Y. Ando   M. Ishida   A. Baba              

Abstract Details

Purpose:

To examine if oral intake of mineralcorticoid receptor inhibitor, eplerenone, has a dose-dependent effect for serous retinal detachment in patients with chronic central serous chorioretinopathy.

Setting:

Retrospective, observational study at Kitasato Institute Hospital

Methods:

The medical records of 25 Japanese patients with chronic CSC with serous retinal detachment who had received oral eplerenone were retrospectively reviewed. The central macular thickness (CMT) and best-corrected visual acuity (BCVA) were measured at baseline, 1 month and 3 months after commencement of oral eplerenone. The dose of eplerenone was determined as 12.5mg, 25mg, or 50mg per day.

Results:

The mean age of the 25 patients (5 women) was 59.5±11.1 years (±standard deviation). All of the patients had at least 5 months of visual symptoms in the affected eye. The mean interval between the onset of CSC and the commencement of eplerenone treatment was 47.6 ± 47.7 months with a range of 5 to 180 months. The average CMT at baseline was significantly reduced from 254±110 µm to 189±64 µm at 3 months (P=0.028; unpaired t test). The patients treated with higher doses of eplerenone were more likely to show the increased changes of CMT at 1 month compared with baseline (rs=-0.42, P=0.044, Spearman's rank correlation coefficient) and 3 months (rs=-0.866, P<0.0001)

Conclusions:

Oral administration of eplerenone was effective for chronic central serous chorioretinopathy and had a dose-dependent effect.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy